Atorvastatin 40 mg	Control	Grey and white matter volumes	1335	1661	All secondary endpoints including number of new lesions and total lesion volume on T2-weighted images, total number of Gd-enhancing lesions on T1-weighted images, volume of grey and white matter, EDSS, MSFC, relapse rate, number of relapse-free patients and neutralizing antibodies did not show significant differences either.
Atorvastatin 40 mg	Control	Gd-enhancing lesions on T1-weighted images	1335	1661	All secondary endpoints including number of new lesions and total lesion volume on T2-weighted images, total number of Gd-enhancing lesions on T1-weighted images, volume of grey and white matter, EDSS, MSFC, relapse rate, number of relapse-free patients and neutralizing antibodies did not show significant differences either.
Atorvastatin 40 mg	Control	Total lesion volume	1335	1661	All secondary endpoints including number of new lesions and total lesion volume on T2-weighted images, total number of Gd-enhancing lesions on T1-weighted images, volume of grey and white matter, EDSS, MSFC, relapse rate, number of relapse-free patients and neutralizing antibodies did not show significant differences either.
Atorvastatin 40 mg	Control	Discontinuation of treatment 	26269	26327	There was no discontinuation of the study drug due to AEs.
Atorvastatin 40 mg	Control	New lesions on T2-weighted images 	24254	24395	The proportion of patients with new lesions on T2-weighted images showed no differences according to the logistic regression model (p = 0.51)
Atorvastatin 40 mg	Control	Grey and white matter volumes	-1	-1	<td align="left" colspan="1" rowspan="1">Median (range)</td><td align="left" colspan="1" rowspan="1">0.7 (−31–30)</td><td align="left" colspan="1" rowspan="1">−1.7 (−42–118)</td><td align="left" colspan="1" rowspan="1">0.81</td>
Atorvastatin 40 mg	Control	Number of relapse-free patients	1335	1661	All secondary endpoints including number of new lesions and total lesion volume on T2-weighted images, total number of Gd-enhancing lesions on T1-weighted images, volume of grey and white matter, EDSS, MSFC, relapse rate, number of relapse-free patients and neutralizing antibodies did not show significant differences either.
Atorvastatin 40 mg	Control	New lesions on T2-weighted images 	1335	1661	All secondary endpoints including number of new lesions and total lesion volume on T2-weighted images, total number of Gd-enhancing lesions on T1-weighted images, volume of grey and white matter, EDSS, MSFC, relapse rate, number of relapse-free patients and neutralizing antibodies did not show significant differences either.
